Alpha Tau announces new positive interim results from the Alpha DaRT® Recurrent Glioblastoma Trial in the US: All treated patients are alive with a median survival not reached, a median of 6.9 months.
🇺🇸 USA · Map
Alpha Tau announces new positive interim results from the Alpha DaRT® Recurrent Glioblastoma Trial in the US: All treated patients are alive with a median survival not reached, a median of 6.9 months.
Want to see every report in real time?
Hundreds of sources worldwide, translated into your language, with alerts for what matters to you.
Sign up free Already have an account? Log in